

## The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated with Convalescent Plasma

Tengfei Ma<sup>1\*</sup>, Chad C. Wiggins<sup>2\*</sup>, Breanna M. Kornatowski<sup>1</sup>, Ra'ed S. Hailat<sup>1</sup>, Andrew C. Clayburn<sup>2</sup>, Winston Guo<sup>2</sup>, Patrick W. Johnson<sup>3</sup>, Jonathon W. Senefeld<sup>2</sup>, Stephen A. Klassen<sup>2</sup>, Sarah E. Baker<sup>2</sup>, Katelyn A. Bruno<sup>4</sup>, DeLisa Fairweather<sup>4</sup>, R. Scott Wright<sup>5</sup>, Rickey E. Carter<sup>3</sup>, Chenxi Li<sup>1</sup>, Michael J. Joyner<sup>2\*\*</sup>, Nigel Paneth<sup>1,6\*\*</sup>

\* indicates equal contribution as first author on the manuscript

\*\* indicates equal contribution as senior author on the manuscript

### Author Affiliations:

<sup>1</sup> Department of Epidemiology and Biostatistics, College of Human Medicine, Michigan State University, East Lansing, Michigan

<sup>2</sup> Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota

<sup>3</sup> Department of Health Sciences Research, Mayo Clinic, Jacksonville, Florida

<sup>4</sup> Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida

<sup>5</sup> Department of Cardiovascular Medicine and Director Human Research Protection Program, Mayo Clinic, Rochester, Minnesota

<sup>6</sup> Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, East Lansing, Michigan

### Correspondence:

Nigel Paneth MD MPH, 218 West Fee Hall, 909 Wilson Road, East Lansing, MI 48823.  
paneth@msu.edu | 517.884.1876

### Funding:

This project has been funded in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority under Contract No. 75A50120C00096. Additionally, this study was supported in part by National Center for Advancing Translational Sciences (NCATS) grant UL1TR002377, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 5T32DK07352 (to CCW), National Heart, Lung, and Blood Institute (NHLBI) grant 5R35HL139854 (to MJJ) and grant 1F32HL154320 (to JWS), Natural Sciences and Engineering Research Council of Canada (NSERC) PDF-532926-2019 (to SAK), National Institute of Allergy and Infectious Disease (NIAID) grants R21 AI145356, R21AI152318 and R21 AI154927 (to DF), Schwab Charitable Fund (Eric E Schmidt, Wendy Schmidt donors), United Health Group, National Basketball Association (NBA), Millennium Pharmaceuticals, Octapharma USA, Inc, and the Mayo Clinic.

1 **ABSTRACT**

2 **Treatment of patients with COVID-19 using convalescent plasma from recently**  
3 **recovered patients has been shown to be safe, but the time course of change in**  
4 **clinical status following plasma transfusion in relation to baseline disease severity**  
5 **has not yet been described. We analyzed short, descriptive daily reports of patient**  
6 **status in 7,180 hospitalized recipients of COVID-19 convalescent plasma in the Mayo**  
7 **Clinic Expanded Access Program. We assessed, from the day following transfusion,**  
8 **whether the patient was categorized by his or her physician as better, worse or**  
9 **unchanged compared to the day before, and whether, on the reporting day, the**  
10 **patient received mechanical ventilation, was in the ICU, had died or had been**  
11 **discharged. Most patients improved following transfusion, but clinical improvement**  
12 **was most notable in mild to moderately ill patients. Patients classified as severely ill**  
13 **upon enrollment improved, but not as rapidly, while patients classified as critically**  
14 **ill/end-stage and patients on ventilators showed worsening of disease status even**  
15 **after treatment with convalescent plasma. Patients age 80 and over showed little or**  
16 **no clinical improvement following transfusion. Clinical status at enrollment and age**  
17 **appear to be the primary factors in determining the therapeutic effectiveness of**  
18 **COVID-19 convalescent plasma among hospitalized patients.**

19           The number of deaths from COVID-19 in the United States surpassed 350,000  
20 on January 3, 2021<sup>1</sup>, just ten months after the first confirmed case of novel coronavirus  
21 (SARS-CoV-2) in the US, demonstrating the urgent need to find safe and effective  
22 treatment options. Convalescent plasma, rich in antibodies from recently recovered  
23 patients, was used successfully in the 1918 influenza pandemic<sup>2</sup>, SARS-1<sup>3</sup> and Ebola<sup>4</sup>  
24 epidemics. Recognizing that a vaccine would not be widely available for several months  
25 to a year, and facing a paucity of treatment options, the United States Federal  
26 Government, in collaboration with the Mayo Clinic and the national blood banking  
27 community, developed the Expanded Access Program (EAP) for COVID-19  
28 convalescent plasma as a national registry to examine the safety and as much as  
29 possible the efficacy of convalescent plasma treatment in hospitalized patients. The  
30 inclusion criteria of the EAP required that enrolled patients 1) have a diagnosis of  
31 SARS-CoV-2, 2) be severely ill or at high risk for becoming severely ill from COVID-19,  
32 and 3) be admitted to an acute care facility for COVID-19 complications.

33           Evidence of efficacy has emerged from retrospective comparisons of treated and  
34 untreated patients<sup>4</sup>, and from several small randomized trials<sup>5-12</sup>. However, only one of  
35 these trials<sup>13</sup> and one retrospective treatment-control analysis<sup>14</sup> in hospitalized patients  
36 stratified patients based on disease severity at time of treatment to examine efficacy  
37 accordingly. Analyses of the EAP have shown that COVID-19 convalescent plasma is  
38 safe<sup>15,16</sup> and likely to be effective in treating COVID-19<sup>17</sup>. Based on the historical  
39 literature, we hypothesized that patients treated with convalescent plasma earlier in the  
40 course of the disease (who were not on mechanical ventilation or in the intensive care  
41 unit (ICU)) or who had less severe disease at the time of transfusion, would show more

42 rapid and better improvement than convalescent plasma recipients receiving  
43 mechanical ventilation or in the ICU at the time of treatment.

#### 44 **THE RAPID EVALUATION PROJECT (REP)**

45 The EAP was developed primarily as a registry to investigate the safety of  
46 convalescent plasma as a treatment for COVID-19 during an ongoing pandemic. It was  
47 implemented at a time when health systems were overwhelmed and clinical research  
48 resources were limited because of hospitals restricting patient access to essential  
49 personnel and the frequent reassignment of research staff to clinical duties. We  
50 therefore developed the REP as an optional reporting tool requiring minimal time and  
51 effort on the part of the treating physician, but that would nonetheless provide useful  
52 information as to whether improvement or worsening was noted following treatment with  
53 convalescent plasma, and how this varied by category of patient.

54 We offered all physicians enrolling patients in the EAP the opportunity to  
55 participate in the Rapid Evaluation Project (REP) by providing brief, daily updates of the  
56 status of their patients until death or discharge from the hospital. Physicians or their  
57 designees, after providing the baseline status of each participant on the day of  
58 enrollment, described each participant's status compared to the previous day – better,  
59 the same, or worse - and also noted whether the patient had been discharged from  
60 hospital or died that day, and whether the patient was in an ICU or had required  
61 mechanical ventilation.

62 This simple system was inspired by the study by Waller and Lawther who asked  
63 London patients with chronic obstructive pulmonary disease to record their daily status

64 – ‘better, worse, much worse, or the same as usual’ - and used these scores to  
65 document a clear relationship of worse days to specific components of air pollution<sup>18,19</sup>.

## 66 **RESULTS**

### 67 **Patient Demographics and Baseline Severity**

68 Sufficient follow-up information was submitted on 8,311 convalescent plasma  
69 recipients. Descriptions of the demographics and disease characteristics are presented  
70 in Table 1. 534 patients were excluded due to receipt of multiple transfusions during  
71 their hospitalization, and another 597 patients who had less than two days of follow-up  
72 data, leaving a total of 7,180 patients for analysis. Participants in the REP were very  
73 similar to the overall EAP population, at the time of data analysis (August 1, 2020), in  
74 age distribution, sex, race and initial clinical status, but tended to have slightly more  
75 respiratory risk factors such as dyspnea, low oxygen parameters and extensive early  
76 lung infiltrates. Compared to the entire EAP cohort (Table 1, third column), there were  
77 fewer Hispanic/Latino patients and more patients residing the Midwest and the West  
78 regions of the U.S, and fewer in the Northeast. Patients were severely ill, with 53% in  
79 an ICU and 28% requiring mechanical ventilation prior to transfusion with convalescent  
80 plasma.

81

### 82 **Score Trajectories Following Transfusion**

83 We constructed ordinal scales of clinical outcome from the physicians’ reports  
84 ranging from -2 to +2. Death was scored as -2, clinical worsening as -1, no change as 0,  
85 clinical improvement as +1, and hospital discharge as +2. Figure 1 displays the  
86 trajectories of mean ordinal scale scores for all patients (Figure 1A) and for several

87 patient sub-groups (Figures 1B-1G) for the first 21 days following CP transfusion, with  
88 gray bands surrounding score trajectories indicating the 95% confidence intervals. More  
89 detailed methods regarding the daily patient scoring can be found in the data analysis  
90 section.

91 For all patients in the REP (Figure 1A), the mean daily score increased rapidly  
92 from one day after CP infusion (mean=0.16, 95% CI: 0.14 - 0.19) to day 8 (mean=0.82,  
93 95% CI:0.78 - 0.87). Thereafter, the mean scores stabilized between 0.82 to 0.91.

94 When stratified by age group (Figure 1B), only the elderly (80+ years old) did not  
95 improve following transfusion but remained on average in the same status as at the time  
96 of transfusion two weeks following infusion (Day 14, mean= 0.002, 95% CI: -0.15, 0.15).  
97 While patients under 55 years of age improved more rapidly than patients 80 years and  
98 older, no substantial difference in improvement was seen between patients aged 18-34  
99 years and patients aged 35-54. Overall, women tended to improve slightly more rapidly  
100 than did men, but both sexes exhibited overall improvement following treatment with  
101 convalescent plasma (Figure 1C).

102 When stratified by baseline category of illness severity (Figure 1D), patients with  
103 mild/moderate illness and severe illness improved most rapidly through day 7 and 9,  
104 respectively, and then leveled off. Patients described as critical/end-stage worsened  
105 from day 1 (mean= -0.04, 95% CI: -0.15, -0.04) onward following the transfusion to day  
106 9 (mean= -0.26, 95% CI: -0.37, -0.16) and then slightly improved but with scores still  
107 remaining negative from day 9 to day 21 (mean= -0.19, 95% CI: -0.31, -0.08). Among all  
108 patients discharged from the hospital during the period of observation, the median

109 length of stay following transfusion was 6 days (IQR= 4-11 days), and among patients  
110 who died, median length of stay following transfusion was 8 days (IQR= 4-13 days).

111 The leveling off of improvement after day 9 in the overall patient population  
112 (Figure 1A) appears to be attributable to patients still being hospitalized after that time  
113 may remain critically ill but medically stable. Very long lengths of stay have been  
114 observed in some patients surviving with COVID-19<sup>20</sup>. Patients not in the ICU at the  
115 time of convalescent plasma treatment (Figure 1E) improved more steadily than  
116 patients in the ICU. Patients who did not require mechanical ventilation at the time of  
117 convalescent plasma treatment (Figure 1F) had better improvement than patients  
118 requiring mechanical ventilation. Patients on ventilators declined steadily for two  
119 weeks, after convalescent plasma treatment (mean= -0.59, 95% CI: -0.69, -0.50).

120 Our analysis revealed that the trajectories of improvement or worsening change  
121 over time, and our statistical program was able to detect the break points indicating  
122 where the curve changed, which in all cases was a levelling off of the initial trajectory.  
123 Table 2 shows the day of the segment breakpoint for several sub-groups of the study  
124 population. The largest factor determining both direction of the trajectory and the  
125 rapidity of stabilization was ventilator status, with unventilated patients stabilizing, after  
126 improvement, after 7-8 days, while ventilated patients did not begin to stabilize from  
127 their downhill course until 12-13 days.

## 128 **Multivariate Analysis of Factors Associated with Trajectories**

129 To assess the individual and combined contributions of the factors described  
130 above (age, gender, ICU status, ventilator status at the time of transfusion, and a

131 qualitative measure of baseline illness severity), we undertook a multivariate approach  
132 (Table 2), using a generalized estimating equations (GEE) model. The cumulative odds  
133 ratios from the GEE model indicate the odds for being in a higher category of the ordinal  
134 scale (net improvement or +1 on ordinal scale compared to day of infusion). Advanced  
135 age ( $\geq 80$  years old) (OR = 0.26, 95% CI, 0.22-0.31,  $P < 0.0001$ ), and critical illness upon  
136 enrollment were the strongest predictors of non-improvement following convalescent  
137 plasma treatment. ICU (OR = 0.46, 95% CI, 0.42-0.51,  $P < 0.0001$ ) and ventilator status  
138 (OR = 0.42, 95% CI, 0.37-0.47,  $P < 0.0001$ ) were next in importance, and gender (OR =  
139 0.93, 95% CI, 0.86-1.01,  $P = 0.07$ ) showed little discrimination once other factors were  
140 taken into account.

141 By day 7, patients who were critical/end stage were 80% less likely to show  
142 improvement compared to mild/moderate cases (OR= 0.21, 95% CI, 0.17-0.25,  $P$   
143  $< 0.001$ ), but by day 21, critical/end stage patients were just 40% less likely to have  
144 improved than the most favorable group (OR= 0.60, 95% CI, 0.39-0.92,  $P = 0.019$ ). The  
145 severe illness group showed substantially less improvement than the mild/moderate  
146 group at both day 7 (OR= 0.45, 95% CI, 0.39-0.52,  $P < 0.0001$ ) and day 21 (OR= 0.65,  
147 95% CI, 0.44-0.98,  $P = 0.039$ ), although as with critically ill patients, the odds ratio of the  
148 severely ill did show some signs of improvement over time.

## 149 **DISCUSSION**

150 The aim of the Rapid Evaluation Project was to answer whether, how quickly,  
151 and to what extent COVID-19 patients improved following the transfusion of  
152 convalescent plasma. Our data describes what happens after convalescent plasma is  
153 given in different sub-groups of patients, and may provide guidance for physicians about

154 the best candidates to receive convalescent plasma to treat COVID-19. We cannot, of  
155 course, conclude that these trajectories are solely the result of convalescent plasma  
156 infusion.

157 We found that most patients who received COVID-19 convalescent plasma  
158 improved within the first 7-10 days following the transfusion. The trajectory of change in  
159 patients infused with convalescent plasma varied greatly depending on their disease  
160 state at the onset of treatment, and we found that some categories of patients did not  
161 appear to show any clinical benefit from convalescent plasma treatment during the first  
162 21 days after treatment, including a) patients who were critical or end stage at the time  
163 of enrollment, b) patients over the age of 80, and c) those on a ventilator at the time of  
164 treatment. The lattermost group actually showed clinical deterioration following  
165 transfusion. Our results also suggest that the rate of clinical improvement in the overall  
166 cohort starts to slow down from day 7, and more noticeably after day 9 from treatment  
167 with convalescent plasma. Despite the slowing of clinical improvement after day 9, in  
168 patients not critically ill, some modest improvement continued at least until 21 days.  
169 Stability of status after the first week of treatment could also mean that convalescent  
170 plasma offers a buffer in time to allow the immune system to mount its own response to  
171 the infection and might mitigate the need for later ICU admission or mechanical  
172 ventilation. At the same time, the slowing of the rate of improvement might suggest  
173 that a second dose of passive antibody could improve outcomes if given 7-10 days after  
174 the first dose in patients whose improvement was sub-optimal<sup>14</sup>.

175 Our analysis provides an estimate of effect size in risk categories while  
176 controlling for other risk factors. We found that several factors ascertained at the time of

177 transfusion were associated with condition change following convalescent plasma  
178 treatment including patients' level of severity; ventilator use, ICU presence, and  
179 advanced age. We also observed that baseline severity is also related to the slope of  
180 the change in trajectory, suggesting that critically ill patients do improve following  
181 treatment with convalescent plasma, albeit at a much slower rate.

182 Overall, the data from our analysis provide a framework for best case use when  
183 considering administering convalescent plasma to treat COVID-19. These data offer a  
184 qualitative supplement to more quantitative analyses from our group<sup>17</sup> supporting the  
185 conclusion that convalescent plasma is a valuable treatment option for many patients  
186 hospitalized due to complications from COVID-19 infection, but most especially if  
187 provided early in the course of disease before patients require ventilation or are  
188 admitted to the ICU.

189

## 190 **METHODS**

### 191 **Study Design**

192           The Mayo Clinic Expanded Access Program (EAP) was a national, multicenter,  
193 open-label registry of hospitalized adults with severe/life-threatening or at high risk for  
194 becoming severe COVID-19 disease, whose physicians treated, or planned to treat  
195 them with convalescent plasma. The initiation and approval of the program have been  
196 described in detail.<sup>5,6</sup> Briefly, hospital and physician registration occurred through the  
197 EAP central website, [www.uscovidplasma.org](http://www.uscovidplasma.org). The web-based registration, compliance,  
198 and data entry system for the EAP went live on April 3, 2020, and the first transfusion  
199 was given on April 7, 2020. Written informed consent was obtained from the patient or  
200 legally-authorized representative prior to enrollment, except for those patients who used  
201 an emergency consent process defined in collaboration with the United States Food and  
202 Drug Administration (21 CFR 50.23). The study was approved and overseen by the  
203 Mayo Clinic Institutional Review Board (IRB #20-003312).

204           The Rapid Evaluation Project (REP) was an optional sub-study of the EAP. The  
205 REP survey was implemented on May 5, 2020. Physicians who opted to participate  
206 were asked to answer three simple questions each day regarding the patient's status  
207 compared to the day before. The survey asked 1) has the patient been in the ICU in the  
208 past 24 hours? 2) has the patient required mechanical ventilation in the past 24 hours?,  
209 and 3) how has the patient's status changed in the last 24 hours?. Possible answers to  
210 question 3 were: a) patient was discharged from hospital, b) patient improved c) patient  
211 stayed the same, d) patient worsened, or e) patient died. Physicians and/or their  
212 designee received an automatic daily notification by email requesting the status update.

213 Participant enrollment in the REP was open to any patient (patient  
214 inclusion/exclusion criteria for EAP described previously<sup>15,16</sup>) in the EAP whose  
215 physician or designee were willing to provide daily updates.

## 216 **Data Analysis.**

217 To define each patient's overall level of improvement or worsening on each day  
218 of observation, we calculated the total number of "condition worsened" and "condition  
219 improved" responses for each patient for the days preceding the day of observation. If a  
220 participant had more "condition worsened" than "condition improved" responses, but  
221 were still alive and still hospitalized, we defined the overall clinical outcome as clinical  
222 worsening (-1) for that day. If the participant had a greater number of "condition  
223 improved" responses, while still hospitalized, we defined the overall clinical outcome as  
224 clinical improvement (+1) for that day. If the participant had the same total number of  
225 "condition worsened" and "condition improved" responses, but still hospitalized, we  
226 defined the overall clinical outcome as no change (0). Finally, death and discharge were  
227 also considered clinical outcomes giving us five potential clinical outcomes to include in  
228 our scale. We used a 5-point ordinal scale to quantify these clinical outcomes as  
229 follows: -2 points, death; -1 point, clinical worsening; 0 points, no change; 1 point,  
230 clinical improvement; 2 points, discharge. To plot group trajectories, we averaged the  
231 ordinal scales of the patient group for each day of observation. To account for the  
232 status of all patients, including those discharged or died, patients were scored as either  
233 +2 or -2 on each day from their discharge or death until day 21.

234 To more fully assess the trajectories, we performed a linear segmented analysis to  
235 identify the changes of scores overtime in each patient group<sup>21-23</sup>. This method allowed us to  
236 test for significantly increasing or decreasing linear trends in clinical outcomes after transfusion.

237 The program examined the data to identify one breakpoint for each segmented regression  
238 model in which the trajectory changed The R package “segmented” was used for the data  
239 analysis[citation 19 20] and  $P < 0.001$  was considered statistically significant.

240 **Multivariate Analysis.** A generalized estimating equations (GEE) approach with a  
241 logit link and independence “working” correlation structure was used to study the effect  
242 of age, sex, level of severity, baseline ventilator use, and baseline ICU admission when  
243 the transfusion was administered. The model included the clinical status  
244 (worsening/improvement) defined above on days 7, 14 and 21 as repeated outcome  
245 measures. Patients who died or were discharged on days other than day 7, 14, or 21  
246 were considered deceased or discharged on the next interval. For example, a patient  
247 who died on day 8 would be categorized as deceased on day 14. To model the effect of  
248 baseline level of severity on different time points, the regression model included a time-  
249 varying term for baseline level of severity. All statistical analyses were completed using  
250 R version 4.0.2. R package “multgee” was used for GEE analysis of ordinal multinomial  
251 responses<sup>24,25</sup> and  $P < 0.05$  was considered statistically significant.

252

## References

1. U.S. Department of Health & Human Services. CDC COVID Data Tracker. (2020).
2. Luke, T. C., Kilbane, E. M., Jackson, J. L. & Hoffman, S. L. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? *Ann. Intern. Med.* **145**, 599–609 (2006).
3. Mair-Jenkins, J. *et al.* The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. *J. Infect. Dis.* **211**, 80–90 (2015).
4. Van Griensven, J. *et al.* Evaluation of convalescent plasma for Ebola virus disease in Guinea. *N. Engl. J. Med.* **374**, 33–42 (2016).
5. Li, L. *et al.* Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. *J. Am. Med. Assoc.* (2020).
6. Gharbharan, A. *et al.* Convalescent Plasma for COVID-19. A randomized clinical trial. *medRxiv* (2020) doi:10.1101/2020.07.01.20139857.
7. Avendano-Sola, C. *et al.* Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial. *medRxiv* 2020.08.26.20182444 (2020) doi:10.1101/2020.08.26.20182444.
8. Rasheed, A. M. *et al.* The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. *Infez. Med.* **28**, 357–366 (2020).
9. Agarwal, A. *et al.* Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). *bmj* **371**, (2020).
10. AlQahtani, M. *et al.* Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. *medRxiv* (2020).
11. Libster, R. *et al.* Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. *N. Engl. J. Med.* **0**, null.
12. Simonovich, V. A. *et al.* A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. *N. Engl. J. Med.* (2020).

13. Li, X. *et al.* Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J. Allergy Clin. Immunol.* **146**, 110–118 (2020).
14. Salazar, E. *et al.* Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG. *Am. J. Pathol.* (2020).
15. Joyner, M. J. *et al.* Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. *J. Clin. Invest.* (2020).
16. Joyner, M. J. *et al.* Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. *Mayo Clin. Proc.* (2020).
17. Joyner, M. J. *et al.* Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience. *medRxiv* (2020) doi:10.1101/2020.08.12.20169359.
18. Lawther, P. J., Waller, R. E. & Henderson, M. Air pollution and exacerbations of bronchitis. *Thorax* **25**, 525–539 (1970).
19. Waller, R. E. & Lawther, P. J. Some observations on London fog. *Br. Med. J.* **2**, 1356 (1955).
20. Bhatraju, P. K. *et al.* Covid-19 in critically ill patients in the Seattle region—case series. *N. Engl. J. Med.* **382**, 2012–2022 (2020).
21. Muggeo, V. M. & others. Segmented: an R package to fit regression models with broken-line relationships. *R News* **8**, 20–25 (2008).
22. Muggeo, V. M. & Muggeo, M. V. M. Package ‘segmented’. *Biometrika* **58**, 516 (2017).
23. Wagner, A. K., Soumerai, S. B., Zhang, F. & Ross-Degnan, D. Segmented regression analysis of interrupted time series studies in medication use research. *J. Clin. Pharm. Ther.* **27**, 299–309 (2002).
24. Touloumis, A. R package multgee: A generalized estimating equations solver for multinomial responses. *ArXiv Prepr. ArXiv14105232* (2014).
25. Noorae, N., Molenberghs, G. & van den Heuvel, E. R. Gee for longitudinal ordinal data: Comparing R-geepack, R-multgee, R-repolr, SAS-genmod, SPSS-genlin. *Comput. Stat. Data Anal.* **77**, 70–83 (2014).

**Table 1.** Demographic factors and disease severity in patients in the Rapid Evaluation Program and the overall Expanded Access Program<sup>†</sup> patients.

	Rapid Evaluation Project Sample <sup>†</sup>	Total EAP Enrollment <sup>†</sup>
<b>Patient Characteristics</b>		
Total patients enrolled	9,752	50,385
Enrolled patient received a transfusion	8,311	--
Patients excluded due to insufficient follow-up <sup>a</sup>	381	--
Received >1 transfusion <sup>b</sup>	534	2,522 (5.0%)
Patients included in the analysis	7,180 (100%)*	50,385 (100%)*
<b>Patient Outcomes</b>		
Discharge reported <sup>c</sup>	4,435 (60.0%)	26,710 (53.0%)
Death reported	1,659 (22.4%)	10,947 (21.7%)
<b>Geographic Region</b>		
Midwest	1,521 (20.6%)	8,046 (16.0%)
Northeast	949 (12.8%)	10,650 (21.1%)
Puerto Rico	13 (0.2%)	47 (0.1%)
Southeast	2,319 (31.4%)	14,737 (29.3%)
Southwest	1,107 (15.0%)	9,919 (19.7%)
West	1,487 (20.1%)	6,983 (13.9%)
<b>Categorical Age (yr)</b>		
18 to 34	418 (5.7%)	2,813 (5.6%)
35 to 54	2,043 (27.6%)	13,348 (26.5%)
55 to 79	4,085 (55.2%)	28,479 (56.5%)
80 or older	850 (11.5%)	5,745 (11.4%)
<b>Gender</b>		
Female	2,974 (40.3%)	20,280 (40.4%)
Male	4,395 (59.6%)	29,931 (59.6%)
Undisclosed	8 (0.1%)	43 (0.1%)
<b>Race</b>		
Asian	261 (3.5%)	1,820 (3.6%)
Black or African American	1,464 (19.8%)	9,517 (18.9%)
Other or Unknown	1,903 (25.7%)	12,706 (25.2%)
White	3,768 (50.9%)	26,342 (52.3%)
<b>Ethnicity</b>		
Hispanic/Latino	2,585 (35.0%)	19,200 (38.1%)
Not Hispanic/Latino	4,811 (65.0%)	31,185 (61.9%)
<b>Initial Clinical Status</b>		
Mild or Moderate	2,387 (34.2%)	--
Severe	3,004 (43.1%)	--
Critical or End Stage	1,565 (22.5%)	--

<sup>†</sup> All enrollment information as of August 3, 2020

\* Following subsections are based on this value

<sup>a</sup> Insufficient follow-up include, no daily reporting for a patient, no dates of submitted reports

<sup>b</sup> Defined as >4 h between transfusions. Multiple units given within 4 h would be considered a single transfusion

<sup>c</sup> Number of patients reported discharged or expired within 21 days of convalescent plasma treatment

<sup>d</sup> These data include a subset of the sample (n = 32,928) - only those patients that currently have severe or life-threatening COVID-19.

**TABLE 2 : Segment breakpoints in first segment coefficient by patient characteristics**

Subgroup Category	Segment Breakpoint	First Segment Coefficient
<b>Overall Cohort</b>	7.4	0.102*
<b>Age</b>		
18-34 years old	7.6	0.171*
35-54 years old	6.5	0.183*
55-79 years old	7.5	0.081*
80+ years old	7.8	-0.007
<b>Sex</b>		
Males	7.5	0.092*
Females	7.3	0.115*
<b>Disease Severity</b>		
Mild or moderate	6.4	0.186*
Severe	8.3	0.096*
Critical or end stage	8.4	-0.034*
<b>ICU Status</b>		
Not in ICU	6.4	0.185*
In ICU	10.4	0.021*
<b>Ventilator Status</b>		
Not on ventilator	7.4	0.143*
On ventilator	12.3	-0.043*

All regression models were analyzed with 2 segments to assess changes and trends of the clinical outcome of each day.

\* indicates  $P < 0.001$  for that segment of the trajectory.


**Table 3:** Multivariate analysis of improvement trajectory based on demographics and disease severity prior to treatment with COVID-19 convalescent plasma

Variables	OR (95% CI)	P value
<b>Intensive Care Status</b>		
ICU admission prior to transfusion	0.46 (0.42-0.51)	<0.0001
<b>Mechanical Ventilation Status</b>		
On ventilator prior to transfusion	0.42 (0.37-0.47)	<0.0001
<b>Sex</b>		
Females	1.00 (Ref)	--
Males	0.93 (0.86-1.01)	0.070
<b>Age</b>		
18-34 years	1.00 (Ref)	--
35-54 years	0.85 (0.73-0.99)	0.044
55-79 years	0.50 (0.43-0.58)	<0.0001
80+ years	0.26 (0.22-0.31)	<0.0001
<b>Odds ratio of Net Improvement by Day 7 Stratified by Disease Severity</b>		
Mild or moderate	1.00 (Ref)	--
Severe	0.45 (0.39-0.52)	<0.0001
Critical or end stage	0.21 (0.17-0.25)	<0.0001
<b>Odds ratio of Net Improvement by Day 14 Stratified by Disease Severity</b>		
Mild or moderate	1.00 (Ref)	--
Severe	0.57 (0.45-0.73)	<0.0001
Critical or end stage	0.31 (0.23-0.41)	<0.0001
<b>Odds ratio of Net Improvement by Day 21 Stratified by Disease Severity</b>		
Mild or moderate	1.00 (Ref)	--
Severe	0.65 (0.44-0.98)	0.039
Critical or end stage	0.60 (0.39-0.92)	0.019

Adjusted GEE model was used to estimate the odds of being in a higher category (net improvement) of the ordinal clinical outcomes.

\*Initial status of severity and time interaction term were added in the model as time-varying covariate.

Figure 1.



## **Figure Legend:**

**Figure 1. Trajectories of Daily Status Improvement/Worsening.** Subgroup analyses include A) all patients, B) by age, C) by sex, D) by initial clinical status, E) by ICU status prior to transfusion, and F) by ventilator status prior to transfusion. Net patient scores of 0= no net change, +1= net improvement but still hospitalized, -1= net worsened and still hospitalized, +2= discharged from hospital, and -2= patient expiration. Points are the mean score for each day, and gray bands indicate the 95% confidence interval for each data set.